Drug intelligence / Profile preview

GHB-002

Development stage: Preclinical
Lead developer: Gatehouse Bio
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

GHB-002 is a preclinical-stage therapeutic candidate being developed by Gatehouse Bio for the treatment of Heart Failure with preserved Ejection Fraction (HFpEF). Gatehouse Bio utilizes an AI-powered platform to identify small RNA (sRNA) signatures associated with specific disease states and designs sRNA-based therapeutics to modulate these pathways. GHB-002 is part of the company's cardiovascular pipeline, specifically targeting the complex pathophysiology of HFpEF, a condition characterized by diastolic dysfunction and systemic inflammation for which there are limited targeted therapeutic options.

Beyond the preview

Go deeper on GHB-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GHB-002.

Explore the full profile